A Pilot Study of Rapid Haplotyping Procedure for Personalized Dosing of Dichloroacetate (DCA) in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

March 1, 2016

Primary Completion Date

May 30, 2017

Study Completion Date

November 1, 2017

Conditions
Healthy
Interventions
DRUG

Dichloroacetate (DCA)

Dichloroacetate (DCA) 25 mg/kg oral solution will be administered daily for 5 days.

OTHER

GSTZ1 haplotyping

One teaspoon of blood is collected by standard phlebotomy. Cheek cells are collected by standard brushing. Samples will be analyzed at two independent laboratories to validate methods for GSTZ1 haplotype analysis.

Trial Locations (1)

32610

UF Health: Clinical Research Center, Gainesville

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Medosome Biotec LLC

INDUSTRY

collaborator

Food and Drug Administration (FDA)

FED

lead

University of Florida

OTHER